November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
39 citations
,
June 2019 in “Frontiers in Endocrinology” Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
22 citations
,
March 2017 in “Journal of the Formosan Medical Association” The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.
14 citations
,
March 2019 in “European journal of pharmaceutics and biopharmaceutics” Proretinal nanoparticles improve skin absorption and reduce irritation of topical retinoids.
March 2025 in “Nature Communications” NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.
1 citations
,
January 2019 in “Skin Pharmacology and Physiology” Eplerenone, a mineralocorticoid receptor antagonist, was found to promote hair growth in human hair follicles.
3 citations
,
August 2025 in “Advanced Therapeutics” Engineered cytokines show promise for improving tissue healing and safety in regenerative medicine.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
19 citations
,
September 2008 in “Journal of Cellular Physiology” Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
30 citations
,
February 2023 in “Journal of Investigative Dermatology” OX40-targeted therapies may help treat skin diseases by reducing inflammation and balancing immune responses.
January 2008 in “Springer eBooks” Thyroid hormone may be useful for treating various skin conditions and needs more research.
90 citations
,
August 2006 in “British Journal of Dermatology” PRIDE syndrome includes skin and hair issues from cancer treatment with EGFR inhibitors.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
June 2025 in “Acta Dermato Venereologica” Low-dose Ritlecitinib may help children with stubborn Alopecia Areata.
October 2008 in “Journal of Intellectual Property Law & Practice” The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.
51 citations
,
January 2024 in “Burns & Trauma” Engineered extracellular vesicles can improve tissue repair and regeneration.
5 citations
,
August 2015 in “British journal of dermatology/British journal of dermatology, Supplement” The top research priorities for congenital ichthyosis include long-term side effects of oral retinoids, best topical treatments, and treatments for itch and hair loss.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
2 citations
,
July 2007 in “Cancer biology & therapy” Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
February 2026 in “Molecules” BBR-SA nanomedicine is a safe and effective treatment for breast cancer.
5 citations
,
January 2004 in “Biochimie” Arsenic trioxide effectively treats APL, improving survival rates despite its toxicity.
12 citations
,
July 2020 in “International Journal of Pharmaceutics” Iron oxide nanoparticles improve skin penetration and drug release for hair loss treatment.
August 2025 in “Skin Research and Technology” 39 citations
,
March 2009 in “Dermatology Online Journal” Erlotinib can cause persistent excessive hair growth.
May 2024 in “Drug discovery today” Thyroid receptor β can help develop new drugs to treat hair loss.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
7 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
1 citations
,
January 2024 in “ACS Medicinal Chemistry Letters” TYK2 inhibitors show promise for treating cancer and autoimmune disorders.